Global Bronchopulmonary Dysplasia Market Growth (Status and Outlook) 2023-2029

Global Bronchopulmonary Dysplasia Market Growth (Status and Outlook) 2023-2029

Bronchopulmonary dysplasia, a type of chronic lung disorder, affects newborns, mostly premature and infants. Lungs and bronchi are damaged at the neonatal phase which causes destruction of tiny air sacs known as alveoli. Babies are not born with the disease. The condition is developed when premature infants need aid to breathe for a longer period, leading to inflammation and lung scarring. Infants with this disease exhibit signs and symptoms such as rapid breathing and faster heart rate. The disease is life threatening however, the severity of the disease varies.

LPI (LP Information)' newest research report, the “Bronchopulmonary Dysplasia Industry Forecast” looks at past sales and reviews total world Bronchopulmonary Dysplasia sales in 2022, providing a comprehensive analysis by region and market sector of projected Bronchopulmonary Dysplasia sales for 2023 through 2029. With Bronchopulmonary Dysplasia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bronchopulmonary Dysplasia industry.

This Insight Report provides a comprehensive analysis of the global Bronchopulmonary Dysplasia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bronchopulmonary Dysplasia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bronchopulmonary Dysplasia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bronchopulmonary Dysplasia and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bronchopulmonary Dysplasia.

The global Bronchopulmonary Dysplasia market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

The global bronchopulmonary dysplasia treatment market is expected to expand at a steady CAGR during the forecast period. According to the Journal of Clinical Medicine, 10,000 to 15,000 new cases of the disorder are reported each year in the U.S. alone. High prevalence of the diseases is expected to drive the global bronchopulmonary dysplasia treatment market during the forecast period. According to the WHO, 15 million babies are born preterm which is another factor contributing to the growth of the market. Furthermore, government initiatives, favorable reimbursement policies, launch of novel drugs, strong pipeline, rising premature birth cases, and increase in health care expenditure are factors likely to propel the global bronchopulmonary dysplasia treatment market during the forecast period. Long-term side effects of drugs, high cost of treatment, and lack of awareness in developing countries are factors anticipated to restrain the global market during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Bronchopulmonary Dysplasia market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Surfactant Replacement Therapy
Oxygen Therapy
Supportive Therapy
Others

Segmentation by application
Clinic
Hospital
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Chiesi Farmaceutici
Discovery Laboratories
Takeda Pharmaceutical Company
MediPost
Clarassance
Syntrix Biosystems

Please note: The report will take approximately 2 business days to prepare and deliver.